HCP content translation is the work of translating healthcare professional (HCP) content – sales aids, KOL slide decks, congress materials, medical education programmes, and disease awareness campaigns – for pharma and MedTech companies. It sits under three industry codes (the EFPIA Code of Practice, the ABPI Code 2024, the MedTech Europe Code of Ethical Business Practice) plus Title VIIIa of Directive 2001/83/EC and the UK Human Medicines Regulations 2012.
A PMCPA case has flagged a translated promotional claim in a German sales aid that drifted from the approved core asset. A KOL slide deck for a global congress in Milan has gone out in three languages without an MLR-MRC review record because the LSP returned files in a format the Veeva PromoMats workflow could not ingest. A pre-launch disease awareness campaign for a MedTech diagnostic has been pulled in France because the localised version triggered Codeem complaint procedures.
These situations share one cause. Translation of content directed at healthcare professionals got scoped as a delivery task, when it is part of the medical-legal-regulatory workstream.
This guide is for the medical affairs lead, head of compliance, MLR-MRC chair, brand director, or head of commercial at a pharma or MedTech company shipping content to healthcare professionals across the EU and the UK. It gives you the three industry codes side by side, the promotional vs non-promotional split, the content type matrix, the MLR-MRC workflow integration, the national code differences, and a vendor evaluation checklist. For the deeper read on quality methodology, see the AdHoc cluster piece on medical translation quality assurance, and for an overview of how we structure medical translation work, see our service page.
TL;DR
|
What EU and UK HCP content translation requires
Five regulatory layers shape HCP content translation in 2026. Title VIIIa of Directive 2001/83/EC (Articles 86 to 100) sets the EU legal floor for advertising of medicinal products. The EFPIA Code of Practice (consolidated 26 February 2025) codifies pharma industry self-regulation across EU member states, embodying the principles of the IFPMA Code. The ABPI Code 2024, administered by the PMCPA, governs the UK pharma industry, supplemented by the MHRA Blue Guide and the Human Medicines Regulations 2012. The MedTech Europe Code of Ethical Business Practice handles medical devices and IVDs. Translation must work across all five layers simultaneously, with content drift between them tracked at the claim level.
The EFPIA Code’s first three chapters reflect the requirements of Directive 2001/83/EC directly. Sections 1.01 and 1.02 anchor the foundational rule: a medicinal product cannot be promoted before grant of marketing authorisation, and promotion must be consistent with the particulars listed in the summary of product characteristics. Article 6 limits promotion to those healthcare professionals whose need for, or interest in, the medicine is relevant. National codes apply on top of the EFPIA framework in each EU market: FSA in Germany, Farmaindustria in Spain, Farmindustria in Italy, LEEM with the Codeem charter in France, ENLI in Denmark, IPHA in Ireland (new code effective 1 June 2025), and INFARMA in Poland. The translation supplier needs to understand which framework governs each piece of content at each stage of the workflow.
The promotional vs non-promotional split
Promotional content directed at healthcare professionals is anything designed to promote the prescription, supply, sale or use of a medicinal product (Article 86 of Directive 2001/83/EC; equivalent definition in Regulation 7 of the UK Human Medicines Regulations 2012). It needs full MLR-MRC review against the approved claims library before any translation goes to market. Non-promotional content (medical education, disease awareness, scientific exchange with KOLs, satellite symposia content at international congresses) follows different review rules and reaches the audience without sitting inside the promotional sign-off chain. The promotional vs non-promotional distinction is the legal dividing line that determines how content must be translated, reviewed, and signed off.
Content promoted to healthcare professionals typically includes sales aids and detail aids used by medical sales representatives, branded congress materials (booth panels, branded handouts), HCP-targeted journal advertising, direct mail to HCPs, branded e-detailing slides, and promotional emails. Non-promotional content includes Independent Medical Education programmes funded by industry but conducted by an independent organisation (Article 16 of the EFPIA Code), disease awareness campaigns that carry no product mention, satellite symposia that present scientific content rather than branded claims, scientific exchange with KOLs and HCOs, and non-interventional study communications. The boundary matters because translation suppliers that treat both streams the same way create audit gaps. For the deeper read on the related boundary between HCP-directed content and patient-directed package leaflets, see package leaflet translation.
HCP content types and translation
Content directed at healthcare professionals covers ten or more document types that each carry different translation requirements. Translation cadence, MLR-MRC review depth, in-context review needs, and audit trail expectations vary by type. Buyers who scope HCP translation as one workstream end up underspending on sales-aid in-layout review and overspending on KOL slide deck terminology checks, or the other way round.
| Content type | Promotional or non-promotional | Translation specifics | Review path |
|---|---|---|---|
| Sales aid / detail aid | Promotional | Branded claims, prescribing information, in-layout review for visual hierarchy | Full MLR-MRC |
| KOL slide deck | Depends on branding | Scientific terminology consistency; KOL voice retention | Full MLR-MRC if branded |
| Congress booth panel | Promotional | Prescribing information; in-layout review; CVS-aware (MedTech) | Full MLR-MRC |
| Satellite symposium content | Non-promotional | Scientific terminology; speaker voice | Medical review |
| Independent Medical Education (IME) | Non-promotional | Balanced, educational tone; no branded claim | Medical review |
| Disease awareness campaign | Non-promotional | No product mention; ASA-aware (UK); Codeem-aware (FR) | Medical + regulatory |
| HCP-targeted journal ad | Promotional | Prescribing information; mandatory information per Section 2.01 EFPIA | Full MLR-MRC |
| e-Detailing slides | Promotional | Branded claims; dynamic content; per-locale prescribing information | Full MLR-MRC |
| HCP-targeted email | Promotional | Subject line claim review; prescribing information access via QR (UK) or link (EU) | Full MLR-MRC |
| Patient support programme HCP brief | Mixed | Clinical instruction; branded context | Full MLR-MRC |
In-layout review and the visual fidelity requirement
Sales aids, congress panels, and KOL slide decks fail their MLR-MRC review when the visual hierarchy of the translated version does not match the approved core asset. Prescribing information must remain prominent, claim placement must mirror the original, and the visual relationship between branded element, claim, and references must hold across languages. SmartEdit provides in-layout review so in-country reviewers can see and edit translated content in final layout, removing the need for an InDesign or front-end-tooling licence on the reviewer side. The in-country reviewer is checking that the translated content reads correctly to a healthcare professional in the target market, with prescribing information in the position the reviewer’s eye expects to find it. For HCP-facing software briefs and digital tools, the relevant cluster reference is medical software translation.
The MLR-MRC workflow and translation
MLR-MRC (Medical-Legal-Regulatory or Medical-Regulatory-Compliance) review is the cross-functional sign-off chain through which every promotional asset directed at healthcare professionals must pass before publication. Translation has to integrate with the MLR-MRC workflow rather than run alongside it. The dominant tool across large pharma is Veeva PromoMats. iEnvision and iManage Promotional Materials Management are common alternatives, with several MedTech companies running custom DAM-based review workflows instead. The LSP needs to deliver translated content into the same review queue as the source asset, with the audit trail intact.
Veeva PromoMats and platform integration
Most large pharma companies run Veeva PromoMats as their MLR review backbone. Translated content needs to land in the same Veeva environment as the source, with version control, reviewer assignment, claim-library reference, and approval workflow intact. An LSP that hands over translated files as standalone PDFs creates manual re-upload work, reviewer confusion, and audit-trail gaps. SmartConnect supports API integration with Veeva PromoMats, iEnvision, and DAM platforms so translated assets reach the MLR-MRC reviewer in the same workflow as the source asset. SmartDesk carries the per-project audit trail that PMCPA, national code committees, and internal compliance audits expect.
The claims library and the approved core asset
The approved core asset is the master sales aid, KOL deck, or detail aid signed off by MLR-MRC in the source language. Every translated derivative must stay inside the approved claims library. Drift between the claim in the source and the claim in the translation is the most common trigger for PMCPA complaints (UK), Codeem complaints (France), or FSA Arbitration Board cases (Germany). The LSP’s terminology management discipline against the claims library is the operational control point: every claim mapped to a translation memory entry, every translation memory entry version-controlled against the approved English claim. Every claim that a healthcare professional reads in a translated sales aid must trace back to an approved claim in the source claims library. Terminology management across the claims library is the cluster’s most important technology dependency for promotional work. Where KOL decks reference clinical trial data, see clinical trial translation for the parallel discipline on CSR-aligned wording.
National code differences across the EU and UK
The EFPIA Code sets the framework, but each major EU market and the UK has its own national code that interprets and extends the framework. The same HCP asset needs different handling per market. Naming a sales aid “promotional material under the FSA Code” in Germany is not the same as naming it “promotional material under Farmindustria” in Italy. The translation supplier needs to know which national code governs the healthcare professional audience in each market and how the local regulator interprets the EFPIA framework, flagging national-code divergence at the translation stage rather than letting the brand team discover the problem after launch.
| Market | Code | Administering body | Key 2024–2025 development |
|---|---|---|---|
| EU framework | EFPIA Code of Practice | EFPIA Codes Committee | Consolidated 26 February 2025; HCP/HCO Disclosure Code alignment |
| United Kingdom | ABPI Code 2024 | PMCPA | Clause 12 QR codes for prescribing information; mandatory written agreements for HCP event support; new Constitution and Procedure (full force 1 January 2025) |
| Germany | FSA Code (HCP/HCO) | FSA Arbitration Board | 2024 reporting period: 12 complaints reviewed; consistent enforcement on scientific event location |
| Ireland | IPHA Code of Practice | IPHA | New version effective 1 June 2025; QR Code rules for promotional and informational materials |
| France | LEEM Code (Codeem charter) | Codeem | Active enforcement on the disease awareness boundary |
| Italy | Farmindustria Code | Farmindustria | Strong scrutiny of digital promotional content |
| Denmark | ENLI Code | ENLI (covers 110 companies) | Pre-vetting procedure with ~400 monthly HCP-directed activity reports |
The UK after the ABPI Code 2024
The ABPI Code 2024 came into force on 1 October 2024 and into full force on 1 January 2025, replacing the 2021 edition. The headline change is Clause 12, completely rewritten in collaboration with the MHRA. Prescribing information can now be provided via QR code on printed promotional material and on certain digital materials presented in person to a healthcare professional (slides at a conference, materials shown on a tablet at a booth). The QR code mechanism is not available for digital materials accessed on the recipient’s own device, such as emails. The translation implication is operational: per-locale QR code destination landing pages, prescribing information consistency with the local SmPC, and version control of the QR-linked content across the campaign lifecycle. Written agreements supporting HCP attendance at events are now mandatory rather than recommended, with the agreement itself a translation artefact when the HCP is in a non-English-speaking market.
The MedTech Europe Code: where MedTech marketing diverges from pharma
The MedTech Europe Code of Ethical Business Practice (March 2024 consolidated version, originally effective 1 January 2017 and revised 25 March 2022 with effect from 1 January 2023) governs medical device and IVD industry interactions with healthcare professionals (HCPs) and healthcare organisations (HCOs). The rules differ meaningfully from the EFPIA pharma framework in three places. Direct sponsorship of individual healthcare professionals at third-party educational events has been forbidden since 2018; educational grants flow only to HCOs (hospitals, scientific societies) which then select beneficiary HCPs. Educational grants must be publicly disclosed. The Conference Vetting System at ethicalmedtech.eu assesses third-party conferences for compliance before MedTech Europe member companies can support them. MedTech promotional content has its own document types: procedure training materials, device demonstration content, hands-on training kits, and IVD launch materials. For the boundary with MDR-related IFU, label, and SSCP translation, see MDR translation requirements.
HCP content translation vendor evaluation checklist
An HCP-content-ready translation supplier combines pharma and MedTech regulatory fluency (EFPIA, ABPI Code 2024, MedTech Europe Code) with MLR-MRC workflow integration capability (Veeva PromoMats, claims library terminology management, in-layout review, per-project audit trail). Most LSPs cover one half or the other; few cover both at the depth a multi-market HCP content programme demands. The checklist below tests for both.
| Criterion | Why it matters for HCP content work | What to ask in the RFP |
|---|---|---|
| ISO 17100 | Process foundation for human translation | Please attach your current ISO 17100 certificate and certification body. |
| ISO 18587 | Required when MTPE is used on promotional copy | Do you hold ISO 18587 for any post-edited MT workflows? Please attach the certificate. |
| ISO 27001 | Information security for confidential promotional content | Please confirm ISO 27001 certification and attach evidence. |
| EFPIA Code fluency | EU pharma self-regulatory framework | Describe how your QMS reflects the EFPIA Code of Practice (consolidated 26 February 2025), including Sections 1.01, 1.02, Article 6, and Article 17. |
| ABPI Code 2024 fluency | UK pharma framework including Clause 12 QR mechanism | Walk us through how your team handles Clause 12 QR-linked prescribing information across translation, in particular the per-locale landing page and version control approach. |
| MedTech Europe Code fluency | Medical device industry framework | Describe how you handle MedTech promotional content where the Conference Vetting System and educational grant disclosure rules apply. |
| National code awareness | FSA, Farmaindustria, Farmindustria, LEEM/Codeem, ENLI, IPHA, INFARMA | How do you flag national-code divergence at the translation stage? Provide an example of a national-code issue you caught before launch. |
| Veeva PromoMats integration | Dominant MLR-MRC platform across large pharma | Confirm API or connector integration with Veeva PromoMats. Walk us through a typical source-to-translated review flow. |
| Claims library terminology management | Approved core asset consistency across translated derivatives | Describe your terminology management approach against an approved claims library. How is each claim mapped, version-controlled, and surfaced to the linguist? |
| In-layout review | Sales aids, congress panels, KOL slide decks need visual fidelity | Can in-country reviewers edit translated promotional content in final layout via your platform without an InDesign licence? |
| Per-project audit trail | PMCPA, national code committees, internal audit | What per-project audit records do you produce, and for how long do you retain them? |
| Multilingual brand and tone consistency | Brand integrity across markets | How do you preserve brand voice across languages while staying inside the approved claims library? |
AdHoc holds current ISO 17100 and ISO 18587 certifications, with the certificates hosted on the AdHoc site for direct verification. SmartDesk carries the per-project audit trail that PMCPA, EFPIA national codes, and MedTech Europe compliance bodies expect. SmartConnect supports API integration with Veeva PromoMats, iEnvision, and DAM platforms. SmartEdit supports in-layout review of sales aids, congress panels, and KOL slide decks so in-country reviewers can confirm the translated content reads correctly to healthcare professionals in each market. For the deeper read on the QA stack across all medical translation work, see medical translation quality assurance.
Frequently asked questions
What is MLR review?
MLR review (Medical-Legal-Regulatory) is the cross-functional sign-off chain through which every promotional asset directed at healthcare professionals must pass before publication. Medical, legal, and regulatory reviewers approve each claim against the approved claims library and the summary of product characteristics. The acronym is sometimes written MRC (Medical-Regulatory-Compliance). Veeva PromoMats is the dominant MLR platform across large pharma; iEnvision and iManage are common alternatives.
What changed in the ABPI Code 2024?
The ABPI Code 2024 came into force on 1 October 2024 and into full force on 1 January 2025. The most significant change is Clause 12, which allows prescribing information to be provided via QR code on printed promotional materials and certain digital materials shown to a healthcare professional in person. Written agreements for HCP event support are now mandatory rather than recommended. A new PMCPA Constitution and Procedure introduces an abridged complaints route for less serious infringements.
What is the difference between promotional and non-promotional HCP content?
Promotional content is anything designed to promote the prescription, supply, sale or use of a medicinal product (Article 86 of Directive 2001/83/EC). It needs MLR-MRC review against the approved claims library before any translation goes to market. Non-promotional content includes Independent Medical Education, disease awareness without product mention, satellite symposia content, and scientific exchange with KOLs. The two streams sit in different review paths and demand different translation governance.
How does the MedTech Europe Code differ from the EFPIA Code?
The MedTech Europe Code prohibits direct sponsorship of individual healthcare professionals at third-party educational events; educational grants flow through HCOs that select beneficiary HCPs. Educational grants must be publicly disclosed. The Conference Vetting System assesses third-party conferences for compliance. Pharma under the EFPIA Code still permits certain direct HCP-targeted activity within national code limits. Different rules, different audit trail requirements for translation.
Speak with our localisation team
If your current translation supplier cannot show you EFPIA + ABPI + MedTech Europe fluency alongside MLR-MRC platform integration and claims-library terminology management, a structured supplier review is the next step. Speak with our localisation team about how AdHoc handles content translation for healthcare professional audiences across pharma and MedTech marketing programmes in the EU and the UK.
Sources
- EFPIA Code of Practice (consolidated 26 February 2025). https://www.efpia.eu/relationships-code/the-efpia-code/. Accessed 14 May 2026.
- EUR-Lex, Directive 2001/83/EC of the European Parliament and of the Council, Title VIIIa (Articles 86 to 100). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20220101
- ABPI Code of Practice for the Pharmaceutical Industry 2024 (published 23 September 2024; in force 1 October 2024; full force 1 January 2025). https://www.abpi.org.uk/publications/code-of-practice-for-the-pharmaceutical-industry-2024/
- PMCPA Constitution and Procedure 2024. https://www.pmcpa.org.uk/the-code/
- GOV.UK, Blue Guide: Advertising and Promoting Medicines (last updated 28 March 2025). https://www.gov.uk/government/publications/blue-guide-advertising-and-promoting-medicines
- MedTech Europe Code of Ethical Business Practice (March 2024 consolidated). https://www.medtecheurope.org/resource-library/medtech-europe-code-of-ethical-business-practice/
- Human Medicines Regulations 2012, SI 2012/1916, Chapter 1 of Part 14.
- IPHA Code of Practice for the Pharmaceutical Industry (new version effective 1 June 2025).
- EFPIA HCP/HCO Disclosure Code.
- IFPMA Code of Practice.
- EFPIA Code Report on Ethics and Compliance Activities (July 2025).
- ISO 17100:2015 and ISO 18587:2017.